Clinical Trials Logo

Filter by:
NCT ID: NCT00619177 Completed - Osteoarthritis Clinical Trials

Assessing the Impact of MOVALIS in Osteoarthritis and Rheumatoid Arthritis Patients on Health Related Quality of Life

Start date: March 2007
Phase: N/A
Study type: Observational

The objective of the observational study is to examine the effect of MOVALIS (Meloxicam) therapy on Health Related Quality of Life (HRQoL) in the diverse region of Central and Eastern Europe. The Medical Outcomes Study 12 Item Short Form Health Survey version 2 (SF-12v2) will be used as the instrument to measure any change in physical wellbeing (Physical Component Summary, PCS) and mental wellbeing (Mental Component Summary, MCS) of patients following MOVALIS (Meloxicam) therapy.

NCT ID: NCT00614939 Completed - Type 2 Diabetes Clinical Trials

Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment

Start date: January 2008
Phase: Phase 3
Study type: Interventional

Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to test the efficacy of once daily saxagliptin in renally impaired patients.

NCT ID: NCT00611026 Completed - Overactive Bladder Clinical Trials

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.

Start date: February 2008
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder

NCT ID: NCT00609674 Completed - Clinical trials for Rhinitis, Allergic, Perennial

A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic Rhinitis

Start date: January 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the effects (effectiveness and safety) of an intranasal corticosteroid (fluticasone furoate nasal spray [FFNS]), with a placebo nasal spray for the treatment of perennial (year-round) allergic rhinitis.

NCT ID: NCT00605215 Completed - Multiple Sclerosis Clinical Trials

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)

BRAVO
Start date: April 24, 2008
Phase: Phase 3
Study type: Interventional

The study aims to compare the effect of daily oral treatment of laquinimod capsules 0.6 milligrams (mg) with the effect of placebo capsules (capsules that contain no active medication) as well as with the effect of an existing Multiple Sclerosis (MS) injectable drug: Interferon β-1a (Avonex®).

NCT ID: NCT00603746 Completed - Asthma Clinical Trials

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy.

Start date: December 2007
Phase: Phase 2
Study type: Interventional

This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.

NCT ID: NCT00603382 Completed - Asthma Clinical Trials

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.

Start date: December 1, 2007
Phase: Phase 2
Study type: Interventional

This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.

NCT ID: NCT00589914 Completed - Schizophrenia Clinical Trials

Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia

Start date: March 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate the effectiveness of paliperidone palmitate in patients with Schizophrenia.

NCT ID: NCT00580216 Terminated - Atrial Fibrillation Clinical Trials

Evaluation of Weekly Subcutaneous Biotinylated Idraparinux Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation

BOREALIS-AF
Start date: December 2007
Phase: Phase 3
Study type: Interventional

The objective is to evaluate whether once weekly subcutaneous (SC) injection of idrabiotaparinux is at least as efficient to prevent clots in brain and in the other organs than oral international normalized ratio (INR) adjusted-dose warfarin in patients with atrial fibrillation (AF).

NCT ID: NCT00578305 Completed - Clinical trials for Rheumatoid Arthritis

A Study of Rituximab (MabThera®/Rituxan®) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate

SCORE
Start date: November 2007
Phase: Phase 3
Study type: Interventional

This 3 arm study assessed the efficacy of rituximab (MabThera®/Rituxan®) in the prevention of progression of structural joint damage in participants with active rheumatoid arthritis who had an inadequate clinical response to methotrexate. Participants were randomized to receive rituximab 500 mg intravenously (iv), rituximab 1000 mg iv, or placebo iv on days 1 and 15 every 24 weeks in the main study; all participants received concomitant methotrexate at a stable dose of 12.5-25 mg/week throughout the study. Further courses of rituximab were provided to eligible participants. Structural joint damage was assessed by magnetic resonance imaging (MRI) at baseline and at intervals during the study.